In the original phase III studies during the first 3 months post-transplantation, 14% of patients in the basiliximab group and 27% of patients in the placebo group had an acute rejection episode treated with antibody therapy (OKT 3 or antithymocyte globulin/ antilymphocyte globulin (ATG/ ALG)), with no increase in adverse events or infections in the basiliximab group as compared to placebo.